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Abstract
Background: The Roland Morris Disability Scale (RMDQ), Visual Analogue Scale of pain 
intensity (VAS) and Numerical Rating Scale (NRS) are among the most commonly used outcome 
measures in trials of interventions for low back pain. Their use in paper form is well-established.
Few data are available on the metric properties of electronic counterparts.
Objective: To establish responsiveness, minimal important change (MIC) thresholds, reliability, 
and minimal detectable change (MDC95) for electronic (e) versions of the RMDQ, VAS, and NRS as
delivered via iOS app, Android app, and web app. 
Methods:  We recruited people with low back pain who visited osteopaths. We invited 
participants to complete the eRMDQ, eVAS, and eNRS at baseline, one-week, and six-weeks, 
along with a health transition question (TQ) at one and six-weeks. Data from participants 
reporting recovery were used in responsiveness and MIC analyses, using Receiver Operator 
Characteristic curves. Data from participants reporting stability were used for analyses of 
reliability (ICC agreement) and minimal detectable change (MDC95). 
Results: We included 442 participants. At one and then six-weeks, ROC AUCs were 0.69 (95%CI 
0.59 to 0.80) then 0.67 (0.46 to 0.87) for the eRMDQ; 0.69 (0.58 to 0.80) then 0.74 (0.53 to 0.95)
for the eVAS; and 0.73 (0.66 to 0.80) then 0.81 (0.69 to 0.92) for the eNRS. Associated MIC 
thresholds were estimated as 1 (0 to 2) then 2 (-1 to 5), 13 (9 to 17) then 7 (-12 to 26), and 2 (1 
to 3) then 1 (0 to 2) points, respectively.  Over one-week in stable and ‘about the same’ 
participants ICCs were 0.87 (0.66 to 0.95) and 0.84 (0.73 to 0.91) for the eRMDQ, with MDC95 of 
4 and 5; 0.31 (-0.25 to 0.71) and 0.61 (0.36 to 0.77) for the eVAS with MDC95 of 39 and 34; and 
0.52 (0.14 to 0.77) to 0.67 (0.51 to 0.78) with MDC95 of 4 and 3 for the eNRS.  
Conclusions: The eRMDQ was reliable with borderline adequate responsiveness. The eNRS was 
responsive with borderline reliability. While the eVAS had adequate responsiveness it did not 
have an attractive reliability profile. Thus, the eNRS might be preferred over the eVAS for 
measuring pain intensity. The observed electronic outcome measures’ metric properties are 
within the range of values reported in the literature for their paper counterparts and are 
adequate for measuring changes in a low back pain population.
Keywords: electronic patient reported outcome measures; validation; responsiveness; 
reliability; minimally important change; minimal detectable change
Introduction
Low back pain (LBP) is a common and costly problem resulting in a substantial personal, social 
and economic burden, and is the number one cause of disability globally.[1, 2] LBP is a symptom 
rather than a specific disease as most LBP is non-specific; i.e. where no specific underlying cause
has been identified, but where the term lacks formal definition and where definitions in trials 
have been diverse.[1, 3] The lifetime prevalence of LBP is between 60-84%. [4, 5] The global 
problem of LBP is getting worse due to aging and increasing population size.[6, 7] The number 
of clinical trials of interventions for LBP has been increasing, with over 30 trials of interventions 
for LBP now being published annually.[8] Patient-reported outcome measures (PROMs) in the 
form of paper questionnaires are typically used in these trials to judge the effectiveness of the 
health technology under investigation.[8]   
Disability and pain are by far the most commonly measured domains in trials of interventions 
for LBP; each is measured at least twice as often as any other domain.[8] The Visual Analogue 
Scale (VAS), and the Numerical Rating Scale (NRS) are most commonly used for measuring pain, 
and the Roland Morris Disability Scale (RMDQ),  is most commonly used for measuring 
disability.[8] These are quasi-continuous measures of pain intensity (VAS, NRS) or functional 
disability, and for each the relationship between the observed item responses and the 
unobserved latent variable each is assumed to be consistent with a reflective conceptual 
framework.[9] There is evidence that paper forms of VAS and NRS have been in use since at least
the early to mid 20th century, and the RMDQ has been used since  1983.[10-12] 
The validity of a PROM is defined as ‘the degree to which an instrument truly measures the 
construct(s) it purports to measure’.[13] Several aspects that comprise what we consider to 
constitute good development and validation of PROMs post-date the introduction of these 
particular instruments. Validation exercises have been performed retrospectively, results have 
accrued over time, and endorsement and use of the measures has survived the process.[14-16] 
Notwithstanding healthy academic debate, it is generally accepted that these outcome measures 
have reasonable face validity, content validity, and have at times been considered the legacy gold
standard for comparison for assessing the criterion/convergent validity of other instruments.
[17-19]
Measuring patient/participant change in health status using browser-based technology and 
mobile device technologies is a natural progression. Digital PROMs and ports of existing paper 
PROMs to digital media have become known as electronic patient reported outcomes measures 
(ePROs).[20] When migrating existing paper PROMs into ePROs, there are aspects relating to the
metric validity of the instrument that may need to be reassessed. Some aspects of validity are 
clearly independent of whether the instrument is completed on paper or digitally—for example, 
the content wording (unless it is culturally/clinically out-of-date), and the extent to which this 
content is judged to appropriately span the domains of the health construct being measured (i.e. 
content and face validity). However, other aspects of validity that relate directly to measurement
performance should not be assumed to be unchanged.   
For any instrument that is designed to measure change in a health construct, two properties are 
particularly relevant: reproducibility (i.e. reliability) and responsiveness. Reliability is the extent
to which the same results are obtained on repeated measures when no real change in health 
status has occurred.[21, 22] An analogy using a set of bathroom weighing scales is that it is 
desirable that the scales show the same weight upon time-standardized daily measurement 
when there truly is no true change in a person’s weight – if this is the case, the scales may be 
said to be reliable.  Conversely, responsiveness is analogous to the scales detecting in important 
change when one truly exists.  As users’ physical interactions with ePRO versions of PROMs 
differs in fundamental respects from paper versions, we suggest that reassessing these two key 
change measurement properties is necessary before advocating their widespread use in health 
research.
In analyses of trials, or evaluations of health interventions, using PROMs to decide when an 
individual participant has responded, facilitates interpretation of intervention effect.[23] 
Responder analysis permits the number of improvements to simply be counted and compared 
by arm using several clear statistics. These are intuitive reporting methods and there is 
consensus that back pain trials should incorporate these.[23-25] However, to be able to do this it
is necessary to know (1) the minimum thresholds considered important to an individual 
participant – the minimally important change (MIC); and (2) what magnitudes of change can be 
detected beyond the inherent measurement error of the instrument – the minimal detectable 
change (MDC).[26, 27] These thresholds may be altered by the change in media from paper to 
digital, and these thresholds may also be population-specific.[28, 29] 
We aimed to determine reliability and responsiveness, MIC and MDC, for electronic versions of 
the VAS, RMDQ, and NRS as administered to adults with LBP who visit osteopaths, using a web 
browser, Android or iOS app on their own computers, smart phones, or tablets. 
Methods
Recruitment
We recruited participants with LBP from osteopathic clinics in England and Wales. Participants 
were recruited by osteopaths on our behalf and provided with an enroll code and instructions 
for installing the iOS or Android app (from the App Store or Google Play) or completing the 
outcome measures using a web browser.
We assumed an attrition rate of 30%, and a recovery (i.e. participants who state they are much 
better or completely recovered on a health transition question – below) rate of over 90% in 
those with acute and sub-acute LBP (i.e LBP present for less than three months).[30] Thus, for 
our responsiveness study, for which we required improved participants, we sought to recruit a 
minimum of 200 people with acute and sub-acute LBP to ensure at least 50 eligible six-week 
measurements (see Sample Size section). For people with chronic LBP receiving manual therapy,
we assumed the same rate of attrition, but a lower rate of recovery, of 45%.[24] For our test-
retest study, we required stable participants who identified as remaining stable over a period of 
one–week; thus, we sought to recruit 400 chronic patients to find 50 participants self-
identifying as stable (i.e. reporting ‘no change’ on a health transition question – below). 
Participants were invited to complete the electronic versions of outcome measures at baseline, 
one-week, and six-week follow-up time points. 
Software
We used Android and iOS apps, and a web app with an associated form builder that was 
developed by Clinvivo Ltd, a University of Warwick spin-out company.[31] The apps, which 
function identically across platforms, permitted PROMs to be typeset and then administered to 
patients securely on their own devices. Data in transit are encrypted using a secure socket layer 
(SSL) and data at rest are encrypted using an Rivest-Shamir-Aldeman (RSA) and Advanced 
Encryption Standard (AES) encryption hybrid. At the end of the study period, data were 
encrypted using the Open Pretty Good Privacy (PGP) standard and transferred from Clinvivo to 
researchers. The iOS, Android, and web apps sent data one-way and did not receive or redisplay 
personal data. The platform presented an electronic version of the instrument and reminded 
participants to complete outstanding follow-up measurements, as appropriate. Off-line 
completion in apps was permitted in cases of interrupted connectivity, with submissions 
occurring upon restoration of connectivity. Reminders, which were received up to twice per 
follow-up measurement due, were sent directly to devices for app-enrolled participants, and 
web-enrolled participants were sent up to two reminder e-mails. 
Electronic Versions of Patient Reported Outcome Measures
The Visual Analogue Scale of Pain Intensity (VAS) is a continuous scale running from 0 to 
100mm, measuring current pain intensity.[32] It is the most commonly used outcome measure 
in trials of interventions for non-specific LBP overall.[8] Huskisson is commonly credited with 
its development in 1974; however, there is evidence that it was being used at least as far back as 
1921.[11] Intellectual Property Rights (IPR) are in the public domain and no permissions are 
required for use, reproductions, or modifications. Completion of the paper scale involves a 
person marking a line on the scale indicating their level of pain between to anchored scales that 
typically have wordings of ‘No pain’ on the left (i.e. 0mm) and ‘Worst possible’ or ‘Worst 
imaginable’ pain on the right (i.e. 100mm).[33, 34] On paper, the distance of the marked line is 
then measured from the point of zero pain and reported in mm. In migrating this to an 
electronic version (eVAS), we implemented a slider that could be dragged into position. We did 
not force the scale to render at 10cm, so as to allow for resizing to screens of different devices. 
Thus, we report scores in units rather than mm, where one unit is 1/100th of the scale (i.e. where
the pointer can be set at any one of 101 different positions), as rendered (Figure 1). 
Figure 1: Electronic Visual Analogue Scale (eVAS) for pain intensity. The figure shows a 
screenshot of the eVAS set to show 63 units of pain intensity
The Roland Morris Disability Questionnaire (RMDQ) is a 24-item questionnaire, measuring 
functional disability due to back pain, which was developed in the early 1980s.[10] It is the most
commonly used outcome measure in trials of interventions for LBP overall.[8] The original 
paper version of the instrument is well established.[35-38] No permissions are required for its 
use, reproductions, or modifications.[39] Scores on the RMDQ range from 0 to 24, where higher 
scores indicate greater disability. Participants are given a statement with which they may 
indicate agreement by ticking a box. Participants are asked to tick statements that they feel 
describe them on that day and to leave blank boxes next to statements that they feel do not. The 
score is then the sum total of checked items. Our electronic (eRMDQ) migration was an exact 
copy utilising multi-select check-boxes (Figure 2). One year into the research we added a box 
stating ‘None of the above symptoms’ for participants to confirm that none of the statements 
applied to them and to confirm zero scores were genuine and not reflective of a skipped 
question. 
Figure 2: Electronic Roland Morris Disability Scale (eRMDQ). The figure shows a screenshot of 
part of the eRMDQ showing a part score of 3 units. 
The NRS is an 11-point ordinal scale measuring current pain intensity.[40, 41] Validation of the 
paper version is well established.[41-43] It is the fourth most commonly used outcome in trials 
of interventions for LBP overall.[8] It is well established with IPR in the public domain. Scores 
on the NRS range from zero, which typically is anchored ‘No pain’, and 10, which typically is 
anchored ‘Worst pain possible’. Our electronic (eNRS) migration was an exact copy with these 
anchor wordings (Figure 3). As the range of responses is exhaustive, completion of the scale was
required for submission.
Figure 3: Electronic Numerical Rating Scale (eNRS) for pain intensity. The figure shows a 
screenshot of the eNRS showing a part score of 6 units. 
Participants were also asked to complete (electronically) a health transition question (TQ) at 
one and six-week follow-up time points. The TQ was a single question with the wording ‘Overall,
how would you rate the change in your symptoms since beginning this study?’ and where the 
participant could respond on a seven-point scale: 1) Completely recovered; 2) Much improved; 
3) Slightly improved; 4) No change; 5) Slightly worsened; 6) Much worsened; 7) Vastly 
worsened.[44]
 
Assessment
We aimed to have 50 completed paired measurements in ‘improving’ participants for 
responsiveness assessments and 50 completed test-retest measurements in ‘stable’ participants.
We defined improving participants, a priori, as participants who select ‘Much improved’ or 
‘Completely recovered’ using the TQ. Improving participants’ scores were used to assess 
responsiveness at one and six-weeks. For our test-retest study, we defined stable participants, a 
priori, as those who select ‘no change’ at one-week, and in the case of having too few 
observations, a post hoc sensitivity analysis including those who selected either ‘slightly 
worsened’, ‘no change’, or ‘slightly improved’. This alternative ‘about the same’ approach to 
marking stability has been used elsewhere.[45] Allowing one-week is typical in low back pain 
test-retest studies; clinically, this is close enough for the people with chronic pain to remain 
stable, but far enough apart that participants cannot easily recall their initial responses. It was 
anticipated that the chronic population would predominantly contribute participants to the test-
retest study, and that improving participants would come from across all chronicity sub-
populations. 
Statistical Analyses
To measure responsiveness in a way that is consistent with the Consensus-Based Standards for 
the Selection of Health Measurement Instruments (COSMIN) definition, we constructed Receiver
Operator Characteristic (ROC) curves for one and six-week data using a dichotomised TQ as the 
external criterion.[22] The area under the ROC curve (AUC) is then a metric of responsiveness, 
accepting that the external criterion reasonably includes the construct of interest.[46] The 
approach has previously been used to quantify responsiveness across all three paper versions of
instruments.[47] ROC AUCs of over 0.70 were considered to be adequate.[9, 48] We 
dichotomized the TQ such that participants responding ‘Completely recovered’ and ‘Much 
improved’ were considered ‘improved’, and all other responses were considered ‘not improved’. 
We also used ROC curves and the TQ external criterion for one and six-week data to quantify 
minimally important change (MIC), which was defined as: “the smallest [change] in score in the 
domain of interest which patients perceive as beneficial and which would mandate, in the absence 
of troublesome side effects and excessive cost, a change in the patient’s management.” (See Note 1 
of Multimedia Appendix 1) [43, 49] We used a MIC estimator based upon the minimum sums of 
squares method, which consistently selects the cut-point closest to the top-left corner of ROC 
space; as required when sensitivity and specificity are valued equally.[50] We calculated 
confidence intervals for MIC point estimates using bootstrapping.[51] 
To estimate reliability, we calculated intra-class correlation coefficients (ICCs).[52, 53] ICC 
values usually range from 0 to 1.[54] ICC values above 0.75 may be interpreted as excellent 
agreement, values of 0.40 to 0.75 indicate poor to fair agreement, and values of below 0.40 
indicate poor agreement.[55] We calculated the standard error of measurement (SEM).[53] We 
used this to estimate the minimal detectable change (MDC95) (See Notes 2 to 4 of Multimedia 
Appendix 1) .[53, 56, 57] 
TQs can be highly correlated with follow-up score rather than change.[24, 43, 58] Guyatt et al 
assert that if a TQ is truly measuring change then a correlation between baseline score and the 
TQ, and follow-up score and the TQ should ideally be present, equal, and opposite.[58] In 
addition, they suggest that in a linear regression model with follow-up score entered as the 
initial explanatory variable, the baseline score should explain a significant proportion of the 
residual variance in the transition rating.[58] We performed Pearson correlations and fitted 
regression models to explore the degree to which the TQ measured change or simply reflected 
follow-up status. Log rank tests were used to assess significance of the addition of baseline 
score. 
  
All analyses were performed using Stata version 14.2 (Statacorp, Texas). The program rocmic 
was used to estimate MIC and the ROC AUC, which for ROC AUC utilises the lroc program.[51, 59]
Power and Sample Size
With the notable exception of construct validity, sample sizes in validation studies generally are 
not calculated based on power to test hypotheses: the estimation of reliability and 
responsiveness parameters is focused on the extent to which the coefficients describing these 
parameters approach 1 (which would represent perfect reliability/responsiveness), rather than 
their difference from zero or some other null value. Generally, a sample size of at least 50 
participants is considered adequate for this purpose.[9, 60] Assuming an ICC of 0.7, with 50 
participants we would be able to estimate the ICC to within a 95% confidence interval of +/- 
0.14. Alternatively, for an ICC of 0.8, we would be able to estimate to within a 95% CI of +/- 0.10.
[9] For responsiveness, with 50 participants and assuming an AUC of 0.8, and equal numbers of 
cases and non-cases, we would be able to estimate AUC to within a 95%CI of +/- 0.12.[61]  
As standard errors (SEs) for MIC estimates are not readily calculable, we used bootstrapping to 
generate standard errors and 95% CIs.[51, 62] Previous simulation work on the paper-based 
RMDQ in a similar population suggested that 2,500 bootstrap samples was sufficient to ensure 
standard error convergence.[63] To explore whether this is the case for the eRMDQ (and also 
whether it is an appropriate number of replications for the eNRS and eVAS) we simulated SEs by
randomly sampling n observations (with replacement) from our dataset, for an increasing 
number of n; where n is an integer, beginning at 20 and increasing by increments of 20, up to 
6,000.[62, 64] We then graphically assessed SE convergence and used the point of convergence 
to inform the number of bootstrap replications. 
Data exclusions, assumptions, and variations
Prior to the addition of the ‘none’ box we imputed zero scores for all baseline submissions with 
no eRMDQ boxes ticked, and assumed and imputed a zero score for eRMDQ follow-up scores in 
the case that the baseline eRMDQ score was greater than zero, and a submission had been made 
for the follow-up period in question. When the eVAS rendered it did so with the slider in the zero
position. In the case of a submission for an untouched eVAS, zero slider zeros were assumed 
valid. The eNRS is a required response and necessitated a selection for submission. 
As part of the basic demographic details we collected, we included a list of presenting 
complaints, featuring LBP among 15 other common musculoskeletal presentations and the 
opportunity to report a complaint not listed in a free-text box. The list of complaints was derived
from earlier survey work developed as part of a national data collection initiative.[65, 66]  We 
excluded all cases where a participant had not checked the LBP box (data from non-LBP cases 
were used in unrelated research).
Ethics approval
Ethics approval was obtained from the research ethics committee at Queen Mary University of 
London (QMERC2014/18). 
Results
User Statistics and Demographics
We collected data from 575 people from 30 osteopathic clinics, between July 15, 2014 and May 
3, 2017. Of these, 442 (77%) reported LBP as their main complaint. The average submission 
time for one-week scores was 7.4 (standard deviation (SD)=0.79) days after baseline. The 
average submission time for six-week scores was 42.5 (SD=0.9) days after baseline. Of the 442 
participants, 267 were female (60%); 306 (69%) identified as being in full or part-time 
employment, five (1%) were long-term sick, 16 (4%) identified as looking after home/family, 87 
(20%) were retired, six (1%) were in full-time education, 13 (3%) were unemployed, and 9 
(2%) selected other or preferred not to disclose. Figure 4 shows a histogram of patient-reported
age at baseline. 
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Figure 4: Histogram of patient age. The figure shows a histogram of patient age at baseline
We collected baseline eNRS data from 442 participants, and eVAS and eRMDQ data from 247 
participants. One-week data were collected from 187 participants and 97 participants 
respectively; and six-week data were collected from 86 participants and 40 participants 
respectively. Figure 5 shows the incidence of recovery in these groups. There was one missing 
data point for eNRS at baseline (0.2%) and one-week (0.5%) for which we were unable to 
confirm cause. Table 1 summarizes ePRO submissions scores and cumulative recovery using 
median and inter-quartile range (IQR). Change scores (not shown) more closely followed 
normal distributions.  
Figure 5: Flow chart showing completion rates at one and six-weeks, chronicity status, and the 
incidence of self-reported recovery using the health transition question, for participants who 
also completed eNRS, and eRMDQ and eVAS measurement (red)
Table 1. Baseline, one-week, and six-week scores across the whole sample
Baseline 
Median 
(IQR)
n One-week 
Median 
(IQR)
n Six-week 
Median 
(IQR)
n
eRMDQ 
4 (6) 247 2 (6) 97 2 (3.5) 40
eVAS
41 (32) 247 24 (19) 97 19 (19) 40
eNRS
5 (4) 441 3 (3.0) 186 2 (2) 91
n (%) n (%)
TQ 
(recovery)
N/A N/A 101 (54) 187 69 (76) 91
Cumulative 
recovery 
(TQ)
N/A N/A 101 (23) 442a 170 (38) 442a
a i.e. as a proportion of all baseline participants
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Figure 6: MIC standard error convergence. A table of graphs showing MIC bootstrap standard 
error (SE) convergence from simulations with increasing replication numbers
The addition of baseline score generally explained a significant proportion of the variance in the 
TQ over and above follow-up score.  The TQ correlated with follow-up score but not with 
baseline score. Comprehensive results for the Guyatt analyses on the TQ’s performance in 
measuring change are listed in Note 2 of Multimedia Appendix 1.
Evaluation Outcomes
Graphically, SE convergence appeared to be asymptotically complete at around 5,000 bootstrap 
replications (Figure 6); thus 5,000 replications were used to generate confidence intervals for 
the MIC estimates in Table 2. Responsiveness point estimates (Table 2) were borderline 
adequate (AUC≈0.7) or above adequate for all instruments and time points. The AUC confidence 
interval for the RMDQ at six-weeks spanned the null value. (Table 2)
Table 2 Responsiveness and minimally important change, by instrument and one-week and six-week follow-up time periods
ROC 
AUC
95% CI n MIC 95% CI
Points/eVAS units 
(% of baseline 
score)
eRMDQ – 
1W
0.69 0.59 to 0.80 97 1 (19%) 0 to 2
eRMDQ – 
6W
0.67 0.46 to 0.87 40 2 (38%) -1 to 5
eVAS – 1W
0.69 0.58 to 0.80 93 13 (32%) 9 to 17
eVAS – 6W
0.74 0.53 to 0.95 40 7 (17%) -12 to 26
eNRS – 1W
0.73 0.66 to 0.80 185 2 (43%) 1 to 3
eNRS – 6W
0.81 0.69 to 0.92 91 1 (21%) 0 to 2
Table 3. Intra-class correlation coefficients from test-retest study in a per protocol stable sample
and a pseudo-stable sample, and associated minimal detectable change thresholds
n ICCagreement 95% CI MDC95
Points/eVAS 
units
eRMDQ – per protocol
15 0.87 0.66 to 0.95 4
eRMDQ – allowing slight 
change
43 0.84 0.73 to 0.91 5
eVAS – per protocol
15 0.31 -0.25 to 0.71 39
eVAS – allowing slight 
change
43 0.61 0.36 to 0.77 34
eNRS – per protocol 22 0.52 0.14 to 0.77 4
eNRS - allowing slight 
change
83 0.67 0.51 to 0.78 3
Using ‘no change’ as a criterion for judging stability, we did not achieve our a priori threshold of 
50 test-retest data points for comparison across any of the instruments. Of the 23 people who 
said they had ‘no change’ at one-week, 15 (65%) had chronic pain. Allowing ‘slightly improved’ 
and ‘slightly worsened’ to count as stable, allowed us to achieve this threshold for the eNRS only.
Of 84 people who said they had ‘no or slight change’ at one-week, 53 (63%) had chronic pain.  
Notwithstanding the lack of data, the eRMDQ reliability (agreement) was excellent using either 
analysis, with CIs spanning fair to excellent in both analyses (Table 3). For the eVAS per protocol 
analysis, the agreement was fair with CIs spanning poor to fair, and in the sensitivity analysis the
agreement was poor to fair with a CI range spanning poor to fair (Table 3). For the eNRS per 
protocol analysis the agreement was poor to fair with a CI spanning poor to excellent, and for 
the sensitivity analysis agreement was fair with a CI spanning poor to fair to excellent (Table 3). 
Discussion
Principal Results
The results suggest that the eRMDQ had borderline adequate responsiveness levels and 
excellent reliability. Conversely, the eNRS had relatively good responsiveness at six-weeks but 
borderline adequate reliability. The eNRS outperformed the eVAS, which had adequate 
responsiveness but relatively poor reliability. As test-retest numbers were few, eVAS confidence 
intervals spanned poor to excellent and thus further investigation is warranted.  While exploring
use by age was not a specific study objective, we note the results indicate encouraging use by 
older people from this population.  
 Comparison with Prior Work 
Across acute and chronic back pain populations there has been like-for-like evaluation (i.e. using
similar and directly comparable methods) of the properties of paper versions of the outcome 
measures explored. ROC AUC for the RMDQ ranges from 0.64 to 0.93. [45, 47, 67-75] ROC AUC 
for the NRS ranges from 0.67 to 0.93.[41, 42, 47, 67, 75, 76] ROC AUC for the VAS ranges from 
0.71 to 0.93.[47, 72, 77-79] Our results are within these ranges at six-weeks for all but our VAS 
estimate at one-week, where our point-estimate approaches the lower border of the range. Our 
eVAS data are nevertheless consistent with the range (i.e insofar as the upper CI overlaps). As 
estimates of ROC AUC for the VAS are fewer in the literature, which might explain why the range 
of reported results is narrower than it is for the RMDQ and NRS. 
MIC thresholds for RMDQ has ranged between 1.5 and 5;[21, 24, 35, 67, 68, 72, 75, 80-83] for 
the NRS between 1.5 and 4;[41-43, 67, 75, 81, 84] and for the VAS between 15 and 28mm.[72] 
Our absolute MIC thresholds are comparable, but are towards the lower side of this range. MIC 
estimates are known to increase with baseline severity and relatively low baseline scores likely 
explain our relatively low thresholds.[68, 75, 81, 84] However, MIC thresholds in our results, 
expressed as percentage change from baseline, averages 28%, which is consistent with Ostelo et
al’s suggestion (following a review of MIC and MDC literature) of using an improvement of 
between 20 and 30% of baseline score for the RMDQ, NRS and the VAS as a MIC threshold.[29] 
We emphasise that the MIC thresholds relate to the degree of change may be considered 
important for an individual, and not what degree of difference may be considered important at a
population-level. [27, 85, 86] We note that negative confidence intervals imply consistency of 
the data with the true MIC thresholds in the opposite direction. This is likely an artifact of low 
power and we suggest inflated sample sizes below for future studies based on the bootstrapped 
standard error observations. 
 
Reported ICC estimates for the RMDQ have ranged from 0.42 to 0.95;[45, 67, 81, 87] for the NRS,
from 0.92 to 0.98;[67, 81] and an estimate for the VAS of 0.71 has been reported.[88] Our results
are within the ranges reported but our ICC point-estimate for the eVAS is lower than the 
reported paper VAS estimate. It is conceivable that rendering the eVAS slider in a zero position 
might lead to additional variance in the case that the outcome is overlooked (i.e. leading to a 
comparatively lower ICC) and future research might explore whether a ‘touch to confirm zero’ 
design is acceptable to users. We also note that some of the ICC values in the literature ranges 
may have been derived from ICCs for consistency rather than agreement; this is a practice that is
known to exist (although it is not always clear which approach is used) and known to 
overestimate reliability.[53]  
MDC95 estimates reported (or, in the case of the NRS only, either reported or where the MDC95 
can be readily calculated from reported SEMs) have ranged from 5.0 to 12.1 for the RMDQ;[21, 
24, 35, 45, 56, 67, 81, 83] from 2.4 to 11 (i.e. the full width of the scale) for the NRS;[41, 45, 67, 
81, 84] and from 21.0 to 33.5 for the VAS.[79, 88, 89] Our estimates are slightly better than 
average for the RMDQ, towards the lower end of the range for the NRS, and comparable to the 
available estimates for the VAS. 
In terms of comparison to studies assessing these instruments as ePROs, Bird et al conducted a 
test-retest study among 22 healthy adults of the VAS administered on iPad and found ICCs of 
0.90 (0.82 to 0.95) as compared to 0.96 (0.92 to 0.98) in a paper version that participants 
completed simultaneously.[90] It is difficult to compare the results with this study, as the time 
between test and retest was less than 30 minutes. A much shorter period between test and 
retest might be appropriate in some populations (e.g. where change in acute pain must be 
measured over short spaces of time). In these cases, participants may be more prone to panel 
conditioning; where second response is affected by recall of the first response.[91] For back 
pain, most interventions focus on chronic pain and longer time periods. When exploring 
reliability of LBP outcome measures, a one-week gap between test and retest is typical.  Bijur et 
al and Gallagher et al have similarly used small time-frames between tests on a paper-based VAS
in acute pain populations and demonstrate similarly high ICCs of 0.97 (0.96 to 0.98) and 0.99 
(0.989 to 0.992) respectively.[92, 93] Also of relevance, but again not directly comparable, is 
work by Bishop et al, who administered the RMDQ on paper and on-line and constructed limits 
of agreement and explored differences between the instruments demonstrating equivalence 
with a score difference of only 0.03 points and a Bland-Altman range of -2.77 to 2.83.[94] 
Finally, we note that the distribution of the user age of the health outcomes app in this 
population appears to be higher than the age of health app users.[95]
Implications
None of the results in this study is materially different from those that have been observed in 
population-similar studies of paper counterparts that are methodologically alike. There is thus 
some suggestion that the ePROs under evaluation are a suitable substitute for PROMs for 
measuring change in LBP.  The eNRS outperformed the eVAS in terms of both responsiveness 
and reliability. As such we suggest the eNRS might be preferred the eVAS for the measurement of
LBP pain intensity, but we caution that subsequent confirmatory research is warranted.
Limitations
The principal limitation is that in several cases we had small sample sizes. We had intended to 
recruit sufficient numbers to have at least 50 people for each assessment, in-line with 
recommendations, but we failed to meet these targets as we underestimated the incidence of 
stability.[9] There were high rates of improvement in people receiving treatment and this is a 
hazard of nesting a test-retest design within a protocol where participants are receiving routine 
clinical treatment. This was of consequence in the eRMDQ responsiveness analysis, where the 
data are consistent with a null population parameter and thus six-week responsiveness of the 
eRMDQ requires confirmation in a larger sample.  Having too few data has greater implications 
for the test-retest assessment of the VAS where the confidence intervals span coefficient values 
that can be interpreted at their extremes as either poor or excellent. It is less of an issue for the 
eRMDQ, as while the numbers are low and lower at one and six-weeks respectively, the stronger 
signal combined with boundary proximity leads to narrower and more useful CIs. 
It is not ideal that we permitted slightly worse and slightly improved to indicate stability in our 
test-retest. Although, we note a similar approach has been observed previously.[45] Further, this
was a post hoc decision taken in light of having too few observations to use our more stringent a 
priori criteria of only those reporting ‘no change’. The results using our a priori approach, but 
with few observations, are offered as sensitivity analyses that may provide useful comparison. 
Having relatively few observations also meant that we were unable to explore differences by 
platform, i.e. iOS, Android, and, web browser, or to explore MIC as a function of baseline score 
(e.g. stratifying by number in category of severity), or separately by chronicity, which may have 
been useful and allowed us to explore any differences in these metrics by chronicity. Thus, our 
focus here is pragmatic and results are generalizable to the population of adults with LBP who 
consult osteopaths, notwithstanding chronicity.   
We recorded in our database only the summed eRMDQ score, rather than individual responses. 
Had we retained detail of individual response profiles of the eRMDQ we could have also 
calculated internal consistency (as well as aspects of modern test theory; e.g. Rasch analysis to 
examine item performance, or factor analysis to explore data dimensionality). Whereas COSMIN 
conflate internal consistency with reliability in their taxonomy,[22, 96] we consider internal 
consistency to be an indication of the unidimensionality of a scale and of item redundancy, 
rather than the degree to which a scale is free from measurement error. As such, and with 
respect to the reliability definition, we preferred to consider it separately. We had not 
immediately considered that completion media type might affect internal consistency or item 
functioning of a scale. On reflection however, we think that it is conceivable that presenting the 
scale digitally may alter the way patients respond. Additionally, there may be self-selection 
effects of those more familiar with digital media joining the study and this may be a factor that 
could be confounded with how a person responds. 
It is not ideal that our TQ correlates with follow-up score but not with baseline score. This is 
emerging to be the case generally and is not something particular to evaluating electronic 
outcome measures.[24, 43, 58] This emergence in our view raises the more general question of 
whether it is appropriate to use TQs at all to evaluate change in outcome measures. Apart from 
being overly driven by follow-up score, the assumption that the TQ is sufficiently driven by the 
same latent construct as the PROM, to the extent that it may be considered a gold standard, may 
be unrealistic. We have previously explored what people think about when they complete the TQ
and what they think about when the complete the paper RMDQ version, and we found 
discordance.[97] Pain appears to be a greater driver of the TQ and the wording of the TQ (i.e. 
attempting to place focus specifically on function or an explicit domain) does not appear to 
matter. In the current study, we used the term ‘symptoms’. However, in the case that the 
suggestion arising from our previous research is incorrect, then using a generic wording in the 
TQ might have the advantage of not favoring any one ePRO over another, but the disadvantage of 
disassociating the TQ from any specific latent health construct. Use of a generically worded TQ 
would then introduce some information bias; for example, if people systematically attend more 
to a particular domain upon reading the word ‘symptoms’. We caution that the logic of this 
typically taken approach of using one outcome measure as a proxy gold standard of recovery, 
and then using this proxy to judge domain-specific responsiveness and MIC thresholds in 
another, may be questionable where there is domain mismatch. 
There was a small amount of missing data at baseline and one-week (one person in each case) 
which should have been impossibility as a selection on the eNRS was a required response. We 
are uncertain of the cause of this but we suspect that this might have been due to use of an 
obscure and/or obsolete browser. 
This research was conducted solely in private care and people who pay to see osteopaths may 
differ from those attending publically funded health care, as is more routinely the case in health 
services research. We note a lower than typical baseline severity (as compared to clinical trials) 
and thus some caution is indicated before generalizing to typical trial populations. Finally, our 
focus here was on the most commonly used domains and outcome measures in trials. The VAS is 
most commonly used overall (pain), RMDQ second most common (disability), and the NRS the 
fourth most commonly used (pain). We did not include the third most commonly used outcome, 
the Oswestry Disability Questionnaire, which also measures disability.[8] Unlike the VAS and 
NRS, which are both single-item instruments, including two full disability questionnaires risked 
being unduly burdensome for participants. Qualitative work suggests that participants would 
prefer to spend only 5-10 minutes completing ePROs.[98, 99] Including a direct comparison 
with paper versions would have permitted direct exploration of criterion validity; however, this 
approach would likely have been affected by panel condition and further added to participant 
burden. 
Recommendations for future research
Sampling stable participants from people receiving routine clinical treatment allows the nesting 
of a test-retest design makes for an efficient design. However, it produces some challenges for 
achieving sufficient recruitment over a realistic time period. It assumes that the TQ classification
of unchanged is valid. As data suggest that TQ is driven more by follow-up state than change, the
approach has some limitations. It would be scientifically preferable that test-retest studies are 
conducted within untreated populations. However, this has both ethical and practical 
implications. When planning to nest a test-retest design within any treatment-containing 
protocol, based on rates observed in this study (using the lower eNRS ‘no chance’ incidence) we 
recommend planning for a study that is around three times larger, i.e. seeking around 1,200 
people to obtain 50 stable participants. For study of responsiveness alone, around 250 
participants should be sufficient to achieve 50 improvements at six-weeks. The most extreme 
MIC threshold we estimated was 7mm (-12 to 26) for the VAS at 6 weeks. This is lower than has 
been noted in studies of paper counterparts. Assuming the point estimate is representative of 
the population parameter, around 300 participants would be required to power a study to 
confirm the finding. 
Retaining data at item level in future studies will permit more sophisticated analytics. There 
may need to be a cultural change as we transition from paper to digital measurement. The 
ability to more easily retain greater data resolution is a clear advantage of digital measurement 
and one that would be sensible to exploit. Further advantages in terms of cost, logistics, form 
validation, reminders, time logging, environmental factors, and reach, are undeniable and, in our
view, make electronic health measurement very attractive. More generally, routine outcome 
measurement in clinical practice will permit learning healthcare systems and so should be a 
shared goal by stakeholders across healthcare.[100, 101] To achieve this, greater collaboration 
may be needed between clinicians, informatics, and policy makers.  We also encourage further 
metric testing of electronic versions these and other legacy PROMs as so that results may inform
health services researchers’ and clinicians’ choices of measure. 
Conclusion
Each of the electronic outcome measures have metric properties that do not materially differ 
from values reported in the literature for their paper counterparts. A possible exception may the
reliability of the eVAS, for which there is insufficient existing research to make useful 
comparisons to the paper version. The eRMDQ is adequate for measuring back-related disability
and the eNRS is adequate for measuring pain intensity. The eNRS should be preferred over the 
eVAS for the measurement of pain intensity. 
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